Higher Efficacy of Blood Gas and Electrolyte Analyzers Driving Adoption in ICUs and Emergency Care
By LabMedica International staff writers Posted on 31 Aug 2022 |
Blood gas and electrolyte analyzers are extensively used for the patients with conditions such as diabetes, hemorrhage, drug overdose, and others. These analyzers detect the blood levels, oxygen concentration, and several parameters for early diagnosis. The global blood gas and electrolyte analyzers market is projected to grow at a CAGR of 5.6% between 2022 to 2030, to reach USD 6.5 billion by 2030, driven by the increasing use of blood gas and electrolyte analyzers in intensive care units (ICUs) and emergency departments. Additionally, the growing adoption of electronic health records (EHR) and development of advanced blood gas analyzers with laboratory information systems, along with higher investment in healthcare services by governments across the world is also expected to drive market growth.
These are the latest findings of Fact.MR (Dublin, Ireland), a market research and consulting agency.
Integration of advanced technology in healthcare devices has been a boon to patients as well as the healthcare industry. The availability of portable blood analyzers coupled with the introduction of automated analyzers have led to increased demand in the market. Portable and fully automated blood and gas electrolyte analyzers require only anticoagulated blood sample and can measure multiple parameters. Hence, healthcare professionals are using these to improve the handling process and accuracy of blood tests. As a result, the demand for blood and gas electrolyte analyzers is predicted to surge by 1.5x over the forecast period.
Going forwards, the efficacy of blood gas and electrolytes in treating patients in critical and emergency situations is likely to drive demand. Consistent quality control and accuracy in error detection will continue to make blood gas and electrolyte analyzers the preferred choice for healthcare providers. Moreover, lack of alternative devices and techniques for measuring oxygen concentration and other parameters for chronic illnesses will also drive sales. However, the high cost of blood analyzers and electrolytes is likely to slow down their adoption rate, especially in the developing countries. In addition, the availability of refurbished devices and slow/non-approval of blood analyzers from FDA could hamper market growth.
By product type, the blood gas analyzers segment is expected to lead the market, owing to its growing use in disease detection. Based on modality, portable blood gas and electrolyte analyzers are anticipated to remain the preferred choice in the healthcare industry owing to their ease of use and affordability. In terms of end user, diagnostic centers and clinical laboratories are expected to witness a steady growth over the projection period. Geographically, North America is expected to be the world’s largest market for blood gas and electrolyte analyzers, with the U.S. leading the demand, while South Asia is expected to be the most lucrative market for blood gas and electrolyte analyzers, with India spearheading the region’s growth through 2022 and beyond.
Latest Industry News
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus
- AMP Publishes Best Practice Guidance for Slice Testing Approach in Diagnostics